ReviewToxins2024
Update on Non-Interchangeability of Botulinum Neurotoxin Products.
Review in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Current Strategies in the Development of Nanoformulations to Enhance the Stability of Botox: A Systematic Review.AAPS PharmSciTech · 2025Pooled it
- OnabotulinumtoxinA in the Management of Pain in Adult Patients with Spasticity: A Systematic Literature Review.Toxins · 2025Pooled it
- A Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores.Toxins · 2025Trial
- Process-dependent Analytical Differences Among Commercial Botulinum Neurotoxin Type A Formulations.Plastic and reconstructive surgery. Global open · 2026Article
- [Botulinum toxin A in the ophthalmological practice: therapeutic and esthetic applications : Indications, prerequisites and procedure].Die Ophthalmologie · 2026Review
- Non-Surgical Ear Rejuvenation Through Selective Neuromodulation with Onabotulinum and Abobotulinum Toxin-A.Toxins · 2026Article
- Botulinum Toxin in Children and Adolescents-A Comprehensive Review of Clinical Applications.Toxins · 2026Review
- [Expert consensus in Southwest China on the application of botulinum toxin type A in upper and mid-facial aesthetics].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Review
- Review
- Botulinum toxin treatment for multiple sclerosis and post-stroke spasticity in clinical practice: differences in injection doses and patterns.Frontiers in rehabilitation sciences · 2026Article
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of OBI-858 for the Treatment of Moderate-to-Severe Glabellar Lines.Dermatology and therapy · 2025Article
- Botulinum Toxin Treatment in Hereditary Spastic Paraplegia-A Comprehensive Review and Update.Toxins · 2025Review
- Antibody-Integrated Solid-to-Gel Microfilm for Protection Against Botulinum Neurotoxin Type A.Gels (Basel, Switzerland) · 2025Article
- Article
- Why Dosing Matters: A Closer Look at the Dose-Response Relationship With OnabotulinumtoxinA.Journal of cosmetic dermatology · 2025Review
- Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights.Journal of clinical medicine · 2025Review
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing use of botulinum neurotoxins (BoNTs) for medical and aesthetic purposes has led to the development and marketing of an increasing number of BoNT products. Given that BoNTs are biological medications, their characteristics are heavily influenced by their manufacturing methods, leading to unique products with distinct clinical characteristics. The manufacturing and formulation processes for each BoNT are proprietary, including the potency determination of reference standards and other features of the assays used to measure unit potency. As a result of these differences, units of BoNT products are not interchangeable or convertible using dose ratios. The intrinsic, product-level differences among BoNTs are compounded by differences in the injected tissues, which are innervated by different nerve fiber types (e.g., motor, sensory, and/or autonomic nerves) and require unique dosing and injection sites that are particularly evident when treating complex therapeutic and aesthetic conditions. It is also difficult to compare across studies due to inherent differences in patient populations and trial methods, necessitating attention to study details underlying each outcome reported. Ultimately, each BoNT possesses a unique clinical profile for which unit doses and injection paradigms must be determined individually for each indication. This practice will help minimize unexpected adverse events and maximize efficacy, duration, and patient satisfaction. With this approach, BoNT is poised to continue as a unique tool for achieving individual goals for an increasing number of medical and aesthetic indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.